Product Description
Il-Yang Pharm is developing Ilaprazole as a treatment for acid-related diseases. (Sourced from: https://www.ilyang.co.kr/english/rnd/rnd03.asp)
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | Ecuador | India | Indonesia | Korea | Mexico | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Il-Yang Pharm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China, Korea
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Generalized anxiety disorder|Injuries/wounds Unspecified|Peptic Ulcer
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IY-NTNS03 | P3 |
Not yet recruiting |
Peptic Ulcer |
2026-08-30 |
33% |
IY-NS250SB | P1 |
Completed |
Healthy Volunteers |
2024-04-13 |
|
CTR20210784 | P3 |
Not yet recruiting |
Generalized anxiety disorder|Injuries/wounds Unspecified |
None |
|
CTR20133004 | P2 |
Recruiting |
Peptic Ulcer |
None |